Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Butenafine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.97 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.47 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.41 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butenafine SCHEMBL29459249 | 1.00 | LMNA (0.97) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL262301 | 1.00 | LMNA (0.97) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL20456391 | 0.99 | CYP2D6 (1.00) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL65526 | 0.99 | CYP2D6 (1.00) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL29354083 | 0.99 | CYP2D6 (1.00) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL1648813 | 0.96 | CYP2D6 (0.94) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Butenafine SCHEMBL500751 | 0.91 | CYP2D6 (0.85) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL9314916 | 0.88 | LMNA (0.76) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| SCHEMBL9695182 | 0.87 | CYP2D6 (0.80) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A | |
| SCHEMBL9312678 | 0.86 | CYP2D6 (0.78) | LMNACYP2D6SLC6A2SIGMAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 838 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332120-A1 | COMPOSITION FOR EXTERNAL PREPARATION | KAO CORPORATION (JP) | 2025-10-30 | — | — | US | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| CN-118817867-A | Method for detecting sodium benzoate in butenafine hydrochloride cream | 山东新时代药业有限公司 | 2024-10-22 | — | — | CN | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| CN-113493388-B | Synthesis method of butenafine hydrochloride | 鲁南制药集团股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-113493384-B | Preparation method of butenafine hydrochloride | 鲁南制药集团股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-113493385-B | Method for synthesizing butenafine hydrochloride | 鲁南制药集团股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | claimed |
| CN-116813479-A | Preparation method of butenafine hydrochloride | 山东新时代药业有限公司 | 2023-09-29 | — | — | CN | claimed |
| US-20020041901-A1 | Pharmaceutical compositions and methods for managing skin conditions | MURAD, INC. | 2002-04-11 | — | — | US | claimed |
| US-20010046478-A1 | Antiinfective combinations and their use for the topical treatment of fungal infections of the toenails and fingernails | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-29 | — | — | US | claimed |
| EP-1071413-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF NAIL FUNGAL DISEASES | Bertek Pharmaceuticals, Inc. (US) | 2001-01-31 | — | — | EP | claimed |
| US-6143794-A | AMINE FUNGICIDES FOR NAILS | BERTEK PHARMACEUTICALS, INC. (US) | 2000-11-07 | — | — | US | claimed |
| WO-2000053186-A1 | TOPICAL COMPOSITIONS CONTAINING A COMBINATION OF AN ANTIFUNGAL AGENT AND A STEROIDAL ANTIINFLAMMATORY AGENT | BERTEK PHARMACEUTICALS, INC. (US) | 2000-09-14 | — | — | WO | claimed |
| US-6075056-A | FOR FUNGI-CAUSED SKIN DISORDERS | PENEDERM, INC. (US) | 2000-06-13 | — | — | US | claimed |
| US-6017920-A | Antifungal composition for external use being retentive in stratum corneum | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-01-25 | — | — | US | claimed |
| WO-1999053913-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF NAIL FUNGAL DISEASES | BERTEK PHARMACEUTICALS, INC. (US) | 1999-10-28 | — | — | WO | claimed |
| EP-0715856-A1 | KERATIN-STORABLE ANTIFUNGAL COMPOSITION FOR EXTERNAL USE | TOKO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1996-06-12 | — | — | EP | claimed |
| EP-0484529-B1 | SKIN CREAM PREPARATION FOR EXTERNAL USE | HISAMITSU PHARMACEUTICAL CO (JP) | 1994-04-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | SLC6A2 806/4885SIGMAR1 1278/4885ADRA2A 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.